A Prospective Pilot Study to Investigate Whether Donor‐Derived Cell‐Free DNA Can Be Used as a Biomarker of Recurrent IgA Nephropathy Post–Kidney Transplantation
International Journal of Immunogenetics · 2025
DOI: 10.1111/iji.70010 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Immunogenetics, 2025. Verfasst von Judith Owusuwaah Asiedu-Basoah und 4 weiteren Autor:innen. Beteiligte Einrichtung: Transplant Laboratory, University Hospitals of Leicester, Leicester, UK. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Kidney Transplantation, Biomarkers, Cell-Free Nucleic Acids. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National School for Healthcare Science (NHS Scientist Training Programme), University Hospitals of Leicester.
Abstract (Originalsprache)
IgA nephropathy (IgAN) is one of the most prevalent glomerulonephropathies and commonly leads to kidney failure. The recurrence of IgAN following transplantation remains a significant concern. Currently, detecting IgAN recurrence requires a kidney biopsy, highlighting the need for non‐invasive biomarkers such as donor‐derived cell‐free DNA (dd‐cfDNA) to aid in early detection. This prospective pilot study aims to evaluate dd‐cfDNA as a non‐invasive biomarker for detecting IgAN recurrence post–kidney transplantation. Specifically, the study seeks to compare %dd‐cfDNA levels in transplanted patients with and without IgAN recurrence and correlate these levels with other kidney function parameters. A total of 32 patients with histologically confirmed IgAN were enrolled, including those with documented IgAN recurrence post‐transplantation and those without recurrence. Plasma samples were collected and processed using the AlloSeq cfDNA kit to quantify relative %dd‐cfDNA levels. Kidney function parameters, including estimated glomerular filtration rate (eGFR) and proteinuria, were also assessed. The study found no significant difference in %dd‐cfDNA levels between transplanted patients with IgAN recurrence and those without recurrence (median 0.37% [IQR 0.28%–3.53%] vs. median 0.42% [IQR 0.15%–0.84%], p = 0.67). Also, %dd‐cfDNA (AUC = 0.57 [95% CI 0.28–0.85], p = 0.64) failed to effectively discriminate IgAN recurrence compared to traditional kidney function parameters such as proteinuria (AUC = 0.96 [95% CI 0.87–1.00], p = 0.002) and eGFR (AUC = 0.74 [95% CI 0.47–1.00], p = 0.09). Relative (%) dd‐cfDNA alone may not be a robust biomarker for detecting IgAN recurrence post‐transplantation. While proteinuria proved a more effective indicator in this study, kidney biopsy remains the gold standard for definitive diagnosis. These findings highlight the challenges of using %dd‐cfDNA as a standalone diagnostic tool for monitoring IgAN recurrence post‐transplantation. Future research should explore larger patient cohorts and longitudinal assessments to refine the utility of dd‐cfDNA and investigate potential combination strategies with other biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Transplant Laboratory, University Hospitals of Leicester, Leicester, UK.
- The University of Manchester, Manchester, UK.
- Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
- Renal Research Department, University Hospitals of Leicester, Leicester, UK.
- TBGBiotechnology, Taipei, Taiwan.
Förderung
- National School for Healthcare Science (NHS Scientist Training Programme)
- University Hospitals of Leicester
Zitieren
APA
Asiedu-Basoah, J. O., Weston, S., Barratt, J., Szklarzewicz, J., & Dunn, P. (2025). A Prospective Pilot Study to Investigate Whether Donor‐Derived Cell‐Free DNA Can Be Used as a Biomarker of Recurrent IgA Nephropathy Post–Kidney Transplantation. International Journal of Immunogenetics. https://doi.org/10.1111/iji.70010
Vancouver
Asiedu-Basoah JO, Weston S, Barratt J, Szklarzewicz J, Dunn P. A Prospective Pilot Study to Investigate Whether Donor‐Derived Cell‐Free DNA Can Be Used as a Biomarker of Recurrent IgA Nephropathy Post–Kidney Transplantation. International Journal of Immunogenetics. 2025. doi:10.1111/iji.70010
BibTeX
@article{AsieduBasoah2025,
author = {Asiedu-Basoah, Judith Owusuwaah and Weston, Stephen and Barratt, Jonathan and Szklarzewicz, Justyna and Dunn, Paul},
title = {A Prospective Pilot Study to Investigate Whether Donor‐Derived Cell‐Free DNA Can Be Used as a Biomarker of Recurrent IgA Nephropathy Post–Kidney Transplantation},
journal = {International Journal of Immunogenetics},
year = {2025},
doi = {10.1111/iji.70010}
}
EUVIMED